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ABSTRACT
Objectives: To establish if using intensive treatment
to reduce synovitis and attain remission in active
rheumatoid arthritis (RA) improves all aspects of
health-related quality of life (HRQoL).
Methods: A secondary analysis of two randomised
clinical trials (CARDERA and TACIT) was undertaken.
CARDERA randomised 467 patients with early active
RA to different disease-modifying antirheumatic drug
(DMARD) regimens, including high-dose tapering
corticosteroids. TACIT randomised 205 established
patients with active RA to combination DMARDs
(cDMARDs) or tumour necrosis factor-α inhibitors
(TNFis). Short-Form 36 (SF-36) measured HRQoL
across eight domains, generating physical (PCS) and
mental (MCS) component summary scores. Linear
regression evaluated 6-month intensive treatment
impacts. Mean SF-36 scores, stratified by end point
disease activity category, were compared with age/
gender-matched population scores.
Results: In CARDERA, intensive corticosteroid
treatment gave significantly greater improvements in
PCS but not MCS scores relative to placebo. In TACIT,
all eight SF-36 domains had improvements from
baseline exceeding minimal clinically important
differences with cDMARDs and TNFis. Significantly
greater improvements with TNFi relative to cDMARDs
were reported in PCS only (p=0.034), after adjusting
for covariates. Remission provided the best SF-36
profiles, but scores in physical functioning, role
physical and general health in both trials remained
below normative values. Patient global assessment of
disease activity had a greater association with HRQoL
than other disease activity score (DAS28) components.
Conclusions: Intensive corticosteroid treatment in
early RA improves physical but not mental health,
relative to placebo. In established RA, cDMARDs and
TNFi provide similar improvements in HRQoL. As
remission optimises but fails to normalise HRQoL,
a focus on treatment strategies targeting HRQoL is
required.
Trial registration numbers: CARDERA was
registered as ISRCTN 32484878. TACIT was registered
as ISRCTN 37438295; pre-results.
INTRODUCTION
Treating rheumatoid arthritis (RA) with
disease-modifying antirheumatic drugs
(DMARDs), biologics and corticosteroids is
primarily intended to reduce synovitis.
Efﬁcacy is assessed by improving composite
measures such as European League Against
Rheumatism (EULAR) response criteria,1 2
Key messages
What is already known about this subject?
▸ An important treatment goal in rheumatoid arth-
ritis (RA) is optimising health-related quality of
life (HRQoL).
▸ It is uncertain if intensive treatment and remis-
sion improve all aspects of HRQoL, with previ-
ous placebo-controlled trials of tumour necrosis
factor-α inhibitors (TNFis) combined with
methotrexate suggesting greater benefits on
physical than mental health.
What does this study add?
▸ This secondary analysis of two randomised clin-
ical trials shows that in early active RA, intensive
corticosteroid therapy improves physical but not
mental HRQoL relative to placebo, and in estab-
lished active RA, intensive treatment with com-
bination disease-modifying antirheumatic drugs
and TNFis has similar impacts on HRQoL.
▸ It also demonstrates that in patients with previ-
ously active RA, attaining remission substantially
improves, but fails to normalise, HRQoL (espe-
cially in established disease), and that the
patient global assessment (PtGA) of disease
activity has a strong association with HRQoL.
How might this impact on clinical practice?
▸ In order to optimise HRQoL in RA, it may be
helpful to place an increased focus on improving
PtGA scores; additional treatments based on
reducing pain, fatigue and improving mood,
which are likely to improve PtGA scores, may be
of benefit in HRQoL.
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which mainly reﬂect reduced joint counts and acute
phase markers. A key secondary goal is improving
health-related quality of life (HRQoL). The
treat-to-target (T2T) approach is based on the concept
that HRQoL is maximised when synovitis is minimised
through escalating drug treatment until patients achieve
remission.3
HRQoL is a broad, multidimensional concept spanning
physical and mental health, function, social support and
socioeconomic status.4 Patients with RA in remission have
substantially improved HRQoL compared with patients in
higher disease activity states.5 However, intensive treatment
and remission may not improve all aspects of HRQoL
equally. Placebo-controlled trials evaluating treatment with
tumour necrosis factor-α inhibitors (TNFis) combined
with methotrexate suggest greater beneﬁts for physical
than mental health in DMARD-inadequate responders
(DMARD-IRs),6 with no impact on mental health in
methotrexate-naïve patients.7 8 Focusing on minimising
synovitis using intensive drug treatment risks overlooking
aspects of HRQoL affected by pain, mood, anxiety, joint
damage and deconditioning.
Our goal was to establish if using intensive treatment
to reduce synovitis and attain remission improves all
aspects of HRQoL. We undertook secondary analyses of
two randomised clinical trials of intensive treatment in
patients with early and established active RA. HRQoL
was captured using the Short-Form 36 (SF-36). We had
three aims: (1) establishing how intensive treatment with
high-dose tapering corticosteroids, TNFi and combin-
ation DMARDs (cDMARDs) affects SF-36 domains; (2)
evaluating the impact of remission and other disease
activity score (DAS28)-deﬁned disease activity categories
on SF-36 domains and (3) evaluating which DAS28 com-
ponents have the strongest associations with HRQoL.
METHODS
Patients
We studied patients in the Combination Anti-Rheumatic
Drugs in Early RA (CARDERA) and TNFi versus com-
bination intensive therapy with conventional DMARDs
in established RA (TACIT) trials; their primary results
have been reported.9 10
CARDERA recruited 467 patients with active early RA
(<2 years duration) from 42 English centres. Patients
were randomised to receive methotrexate alongside
high-dose rapidly reducing corticosteroids,11 ciclosporin,
placebo or both active treatments in a factorial design.
Patients were assessed 6-monthly for 24 months.
TACIT recruited 205 patients with active established
RA (>1 year duration) from 24 English centres. Patients
were randomised to receive (a) TNFi (adalimumab, eta-
nercept or inﬂiximab), with a TNFi switch after
6 months if DAS28(ESR) reduction was <1.2; (b) inten-
sive cDMARDs, with TNFi initiated after 6 months if
DAS28(ESR) reduction was <1.2. Patients were assessed
6-monthly for 12 months.
Health-related quality of life
Short-Form 36
SF-36 evaluated HRQoL in both trials. It measures
HRQoL across eight domains: physical functioning (PF)
—ability to perform physical activities; role physical (RP)
—interference with work and other daily activities;
bodily pain (BP); general health (GH)—how individuals
evaluate their health; vitality (VT)—fatigue, pep and
energy; social functioning (SF)—interference with social
activities; role emotional (RE)—interference with work/
daily activities due to emotional problems; general
mental health (MH)—nervousness and depression.12
These domains are scored 0–100; higher scores indicate
better health. Domain scores can be normalised,
z-transformed and combined into physical and mental
component summary scores (PCS and MCS) providing
summary measures of physical and mental health, rela-
tive to population means of 50 (SD 10).13 The PCS posi-
tively weights the physical domains and VT and
negatively weights the other mental domains; the MCS
positively weights the four mental domains and nega-
tively weights the four physical domains. Weights used
are factor score coefﬁcients derived from the general
population.13 Minimal clinically important differences
(MCIDs) in SF-36 domain and component summary
scores are 5.0 and 2.5 units, respectively.14
Short-Form 6D
SF-36 scores were converted into the Short-Form 6D
(SF-6D), a health utility measure ranging from 0.290
(worst health) to 1.000 (perfect health), using the Ara
and Brazier algorithm.15 16 Its minimum important dif-
ference (MID) is 0.041.17
Analysis time point
We evaluated treatment effects on HRQoL over the ﬁrst
6 months in CARDERA and TACIT for two reasons.
First, the COBRA corticosteroid regimen in CARDERA
(initially 60 mg/day, tapered to 7.5 mg/day by weeks
7–28 and stopped by week 36)11 had maximal effects at
6 months. Second, in TACIT after 6-month cDMARD
treatment, 41% of patients switched to TNFis; 6-month
results speciﬁcally compared TNFi with cDMARDs. To
ensure 6 months was not too early a time point to
observe treatment effects on HRQoL, we undertook a
sensitivity analysis looking at treatment effects on
HRQoL over 12 months (see online supplementary
table 1).
The impact of remission and DAS28 components on
HRQoL was assessed at study end points (24 months in
CARDERA; 12 months in TACIT) when remission rates
were greatest.
Statistical analysis
Impact of treatment on SF-36
Treatment effects were evaluated using linear regression
models including the 6-month changes in each SF-36
domain and summary score as the response variable. An
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unadjusted model included treatment (active vs placebo
corticosteroids in CARDERA; TNFi vs cDMARD therapy
in TACIT) as the explanatory variable. An adjusted
model included treatment, baseline SF-36 domain/
summary score, age, sex and disease duration as
explanatory variables.
Impact of remission and disease activity categories on SF-36
Mean SF-36 domain scores at the ﬁnal time point in
CARDERA and TACIT were plotted on spydergrams
stratiﬁed by (a) DAS28(ESR) activity category: remission
(DAS28(ESR) <2.6), low disease activity (LDA; ≥2.6 to
<3.2), moderate disease activity (MDA; 3.2–5.1), high
disease activity (HDA; >5.1) and (b) remission versus
non-remission according to each DAS28 component:
tender joint count (TJC) ≤1, swollen joint count (SJC)
≤1, patient global assessment (PtGA) of disease activity
on a 100 mm visual analogue scale ≤10, erythrocyte sedi-
mentation rate (ESR) ≤20 mm/hour. These component
cut-offs represent the preliminary American College of
Rheumatology (ACR)/EULAR Boolean-based deﬁnition
of RA remission for clinical trials.18 As C reactive protein
(CRP) data were not available, a normal ESR level was
considered indicative of acute phase response remission.
Associations between DAS28 components and SF-36
summary scores
To minimise type I error from multiple testing (4 DAS28
components; 8 health domains), associations between
DAS28(ESR) components and PCS and MCS were
tested. Linear regression models used ﬁnal time point
PCS and MCS scores as response variables, and SJC,
TJC, ESR and PtGA as explanatory variables, adjusted
for covariates (treatment, age, sex and disease duration).
Model 1 tested each DAS28(ESR) component separately.
Model 2 included all DAS28(ESR) components as
explanatory variables. To ensure multicollinearity
between DAS28(ESR) components was not an issue in
model 2, variance inﬂation factors (VIFs) were calcu-
lated for each predictor; VIF was <2 for all explanatory
variables.19 Standardised β values were calculated enab-
ling direct comparison of effect sizes of each DAS28
(ESR) component on PCS and MCS.
Missing data imputation
In CARDERA, missing data had been imputed at all
time points using last observation carried forward
(LOCF) analysis.10 Missing data were imputed in 19% of
patients at 24 months; an observed case analysis had
excluded a signiﬁcant impact of the LOCF assumption
on the study end points, which included PCS and MCS
scores. For consistency across studies, we imputed
missing TACIT data using LOCF (undertaken at
6 months in 5 and 18 patients for SF-36 domain scores
and DAS28(ESR) components, respectively, and at
12 months in 15 and 16 patients for SF-36 domain scores
and DAS28(ESR) components, respectively). We under-
took an additional analysis using non-imputed TACIT
data to ensure our ﬁndings were not biased by LOCF
imputation (see online supplementary tables 2 and 3).
Normative SF-36 profiles
Age-matched and gender-matched US normative scores
(A/G norms) were generated for CARDERA and TACIT
protocol populations using data published in SF-36
manuals and updates.20 It was not possible to use UK A/
G norms as these data are not publicly available,
although existing studies have highlighted similarities in
mean SF-36 domain scores between UK and US
populations.21 22
Statistical software
Analyses were performed in R (V.3.1.3).
Ethics, consent and permissions
CARDERA (ISRCTN 32484878 and Research Ethics
Committee (REC) reference: MREC (1) 99/04) and
TACIT (ISRCTN 37438295 and REC reference: MREC Ref
07/Q0505/57) were approved by research ethics commit-
tees. All patients provided informed written consent.
RESULTS
Baseline characteristics
In both trials, most patients were female, with a mean
age in the sixth decade (table 1). As expected from the
inclusion criteria for each trial, mean disease duration
in TACIT (8.2 years) was higher than CARDERA
(0.3 years). TACIT patients also had higher baseline
DAS28(ESR) (mean 6.26) compared with CARDERA
(mean 5.78), attributable to higher TJC and PtGA
scores. Baseline health assessment questionnaire (HAQ)
levels were slightly higher in TACIT (mean 1.85) than
CARDERA (mean 1.59). PCS scores were lower in
TACIT (mean 26.0) than CARDERA (mean 29.6); MCS
scores were similar in both trials (CARDERA mean 39.8;
TACIT mean 39.2).
Within-trial comparisons of baseline patient character-
istics between treatment arms showed patients were well
matched (table 1). Signiﬁcant differences were observed
between treatment arms for some SF-36 domains: in
CARDERA, SF, RE and MCS scores were signiﬁcantly
higher in the active steroid group; in TACIT, SF was sig-
niﬁcantly lower in the TNFi group.
Impact of corticosteroids versus placebo on SF-36
domains
In CARDERA, 6-month increases in mean scores exceed-
ing MCID were reported in all eight SF-36 domains with
active and placebo corticosteroids, with the exception of
GH in the placebo arm (ﬁgure 1). Active corticosteroids
resulted in signiﬁcant improvements in all physical
health domains, relative to placebo (table 2). Over
6-months increases in PF, RP, BP, GH and PCS scores
were estimated to be 7.97 (p<0.001), 7.34 (p=0.047),
8.14 (p<0.001), 5.00 (p=0.003) and 3.78 (p<0.001) units
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greater with corticosteroids than placebo, respectively,
when evaluated using the adjusted linear regression
model. In contrast, corticosteroids had no effect on any
mental health domains when evaluated using
unadjusted and adjusted linear regression models.
Despite improving physical health, 6-month SF-36 pro-
ﬁles remained substantially lower than those of A/G
norms (ﬁgure 1). A sensitivity analysis evaluating the
impact of corticosteroids on changes in SF-36 domain
scores over 12 months showed no treatment effect of
corticosteroids compared with placebo, suggesting the
beneﬁts of high-dose tapering corticosteroids on phys-
ical HRQoL are not sustained over time (see online
supplementary table S1).
Impact of TNFi versus cDMARDs on SF-36 domains
In TACIT, 6-month increases in mean scores exceeding
MCID were reported in all eight SF-36 domains with
cDMARDs and TNFi (ﬁgure 1). A total of 6 months of
TNFi therapy provided a signiﬁcantly greater improve-
ment in PCS compared with cDMARD therapy (table 2);
the increase in PCS was estimated to be 3.04 units greater
(p=0.034) with TNFi compared with cDMARDs when
evaluated using the adjusted model. Signiﬁcantly greater
improvements were reported in PF, GH and VT in the
unadjusted model, although these domains lost
signiﬁcance after adjusting for their baseline scores and
other covariates. As in CARDERA, despite TNFi and
cDMARD therapy improving SF-36 domains, HRQoL
remained substantially below that of A/G norms in both
treatment arms (ﬁgure 1). A sensitivity analysis evaluating
the impact of TNFi versus cDMARDs on changes in SF-36
domain scores over 12 months showed no effect of TNFi
versus cDMARDs (see online supplementary table S1).
Impact of remission and disease activity categories on
SF-36 domains
SF-36 domains by DAS28 category
In both trials, increases in all SF-36 domains were
observed with reducing DAS28(ESR) disease activity cat-
egories (ﬁgures 2 and 3). Remission provided the
highest mean SF-36 domain scores in CARDERA and
TACIT.
In CARDERA (ﬁgure 2), patients in remission
reported mean scores 9.6, 2.9, 3.9 and 5.0 units lower
than A/G norms for PF, RP, GH and RE, respectively.
Mean scores in BP, VT, SF and MH were 7.9, 1.6, 3.1 and
4.8 units higher, respectively.
In TACIT (ﬁgure 3), patients in remission reported
mean scores 19.6, 9.8, 3.3, 13.3, 5.7, 3.1 and 0.7 units
lower than A/G norms for PF, RP, BP, GH, VT, SF and
Table 1 Patient baseline characteristics
CARDERA (n=467) TACIT (n=205)
Characteristic Placebo (n=236) Steroids (n=231) p Value cDMARDs (n=104) TNFi (n=101) p Value
Demographic
Number (%) female 157 (67) 166 (72) 0.251 73 (70) 79 (78) 0.249
Age (years) 53.8 (13.6) 54.5 (11.5) 0.567 58.0 (12.9) 56.7 (11.0) 0.459
RA specific
Disease duration (years) 0.3 (0.4) 0.4 (0.5) 0.082 7.3 (8.4) 9.2 (9.2) 0.126
DAS28 5.84 (1.27) 5.71 (1.30) 0.266 6.21 (0.92) 6.30 (0.81) 0.461
SJC 10.0 (6.5) 9.7 (6.1) 0.577 10.5 (6.1) 10.8 (6.7) 0.753
ESR 40.9 (28.9) 40.8 (29.6) 0.979 33.1 (26.1) 30.1 (22.8) 0.379
TJC 12.3 (7.4) 11.3 (7.8) 0.130 16.4 (7.1) 17.5 (6.7) 0.259
PtGA 54.3 (26.7) 55.6 (26.0) 0.582 68.1 (19.7) 68.2 (21.3) 0.988
HAQ 1.59 (0.68) 1.59 (0.69) 0.984 1.80 (0.59) 1.90 (0.67) 0.251
HRQoL
PF 33.6 (24.5) 34.3 (24.0) 0.754 30.1 (22.6) 24.6 (20.9) 0.067
RP 14.4 (29.5) 17.9 (32.8) 0.233 14.9 (30.1) 12.4 (26.1) 0.521
BP 33.2 (21.0) 34.4 (21.4) 0.541 28.1 (16.3) 26.3 (17.8) 0.435
GH 44.4 (21.1) 46.4 (19.9) 0.305 35.8 (18.2) 31.4 (16.8) 0.074
VT 31.2 (20.3) 34.7 (20.7) 0.063 30.3 (21.4) 26.6 (19.0) 0.185
SF 48.3 (31.2) 54.4 (29.7) 0.030 50.2 (25.2) 42.1 (25.3) 0.022
RE 38.3 (43.7) 46.5 (44.9) 0.046 43.9 (44.9) 35.3 (44.9) 0.172
MH 59.5 (20.0) 61.6 (19.0) 0.252 61.9 (20.2) 58.8 (23.1) 0.305
PCS 29.6 (8.5) 29.6 (9.5) 0.969 26.5 (7.5) 25.5 (7.8) 0.356
MCS 38.3 (15.2) 41.3 (14.3) 0.025 40.8 (14.8) 37.6 (14.6) 0.120
Data given as mean (SD) unless otherwise stated; p values for continuous and categorical variables derived from t-tests and χ2 tests,
respectively.
BP, bodily pain; cDMARDs, combination disease-modifying antirheumatic drugs; DAS28, disease activity score; ESR, erythrocyte
sedimentation rate; GH, general health; HRQoL, health-related quality of life; MCS, mental component summary; MH, mental health; PCS,
physical component summary; PF, physical functioning; PtGA, patient global assessment of disease activity; RA, rheumatoid arthritis; RE, role
emotional; RP, role physical; SF, social functioning; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor-α inhibitor;
VT, vitality.
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RE, respectively. Mean scores in MH were 2.7 units
higher.
SF-36 domains by DAS28 component remission
In both CARDERA and TACIT, PtGA-deﬁned remission
resulted in the highest mean domain scores and
ESR-deﬁned remission resulted in the lowest mean
domain scores, compared with remission deﬁned by
other DAS28(ESR) components (ﬁgures 2 and 3).
Association between DAS28 components and SF-36
summary scores
In CARDERA, all four DAS28(ESR) components had
signiﬁcant associations with PCS and MCS scores at
24 months in both models (model 1 testing each compo-
nent separately; model 2 testing all components in same
model) except TJC, which did not have a signiﬁcant
association with PCS in model 2 (p=0.977; table 3).
PtGA had the largest effect on PCS (model 1 standar-
dised β=−0.57) and MCS (model 1 standardised β=
−0.44) scores.
In TACIT, SJC, TJC and PtGA, but not ESR had signiﬁ-
cant associations with PCS and MCS scores in model 1
(table 3); as in CARDERA, the largest effect size was
observed with PtGA (PCS and MCS model 1 standar-
dised β values of −0.43 and −0.41, respectively). Only
PtGA retained a signiﬁcant association with PCS
(p<0.001) and MCS (p<0.001) scores in model 2.
SF-6D utility scores
SF-6D scores improved in CARDERA and TACIT with all
treatments. In CARDERA, SF-6D scores increased from
0.594 to 0.669 (change 0.076) over 6 months with active
corticosteroids, and from 0.577 to 0.633 (change 0.057)
with placebo. In TACIT, SF-6D scores increased from
0.548 to 0.629 (change 0.081) over 6 months with TNFi
and 0.574 to 0.626 (change 0.052) with cDMARDs.
Improvements in both treatment arms in both trials
exceeded MID.
DISCUSSION
We have undertaken secondary analyses of two com-
pleted randomised clinical trials in early and established
RA. Our ﬁrst aim was to evaluate the effect of intensive
treatments—high-dose corticosteroids versus placebo in
early RA, and cDMARDs versus TNFis in established RA
—on SF-36 domains during the ﬁrst 6 months of treat-
ment. With all active treatments, there were improve-
ments in all eight SF-36 domains, which exceeded
MCIDs (5 units). However, in early RA, corticosteroids
only provided improvements beyond placebo in physical
but not mental SF-36 domains. Furthermore, in estab-
lished RA, there were similar improvements with
cDMARDs and TNFis. These results show that in these
two trials intensive treatments resulted in limited add-
itional beneﬁts on HRQoL compared with less intensive
treatments.
Figure 1 Mean Short-Form 36 (SF-36) domain scores at
baseline and 6 months in patients receiving active or placebo
corticosteroids, cDMARDs or TNFis. (A) Patients with early
RA in the CARDERA trial randomised to receive either active
or placebo high-dose tapering corticosteroids (baseline
placebo and 6 months placebo=mean SF-36 domain scores
at 0 and 6 months in patients receiving placebo
corticosteroids; baseline active and 6 months active=mean
SF-36 domain scores at 0 and 6 months in patients receiving
active corticosteroids; A/G norms=mean SF-36 domain scores
in an age-matched and gender-matched normative US
population). (B) Patients with established RA in the TACIT trial
randomised to receive either cDMARD or TNFi (baseline
cDMARD and 6 months cDMARD=mean SF-36 domain
scores at 0 and 6 months in patients receiving cDMARDs;
baseline TNFi and 6 months TNFi=mean SF-36 domain
scores at 0 and 6 months in patients receiving TNFi; A/G
norms=mean SF-36 domain scores in an age-matched and
gender-matched normative US population). BP, bodily pain;
cDMARD, combination disease-modifying antirheumatic drug;
GH, general health; MH, mental health; PF, physical
functioning; RA, rheumatoid arthritis; RE, role emotional; RP,
role physical; SF, social functioning; TNFi, tumour necrosis
factor-α inhibitor; VT, vitality.
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Table 2 Effect of intensive treatment on 6-month changes in SF-36 domains
SF-36 domain
CARDERA TACIT
Model 1: Unadjusted Model 2: Adjusted Model 1: Unadjusted Model 2: Adjusted
β (SE) p Value β (SE) p Value β (SE) p Value β (SE) p Value
PF 7.55 (2.27) <0.001 7.97 (2.18) <0.001 8.61 (3.83) 0.026 5.43 (3.62) 0.135
RP 5.52 (3.94) 0.162 7.34 (3.69) 0.047 5.05 (6.28) 0.423 1.55 (5.78) 0.789
BP 7.59 (2.34) 0.001 8.14 (2.20) <0.001 5.93 (3.29) 0.073 3.97 (2.89) 0.170
GH 4.52 (1.78) 0.011 5.00 (1.68) 0.003 7.38 (2.97) 0.014 4.16 (2.64) 0.117
VT 1.39 (1.86) 0.454 2.60 (1.76) 0.140 7.46 (3.28) 0.024 4.72 (2.91) 0.107
SF 1.86 (2.69) 0.488 4.57 (2.42) 0.060 6.01 (3.94) 0.129 0.11 (3.47) 0.975
RE −1.51 (4.52) 0.739 4.36 (3.82) 0.254 1.72 (7.72) 0.824 −6.93 (6.25) 0.269
MH −0.23 (1.77) 0.898 0.66 (1.61) 0.684 1.09 (3.45) 0.753 −2.25 (2.76) 0.415
PCS 3.84 (1.02) <0.001 3.78 (0.97) <0.001 3.70 (1.51) 0.015 3.04 (1.42) 0.034
MCS −1.33 (1.32) 0.316 0.36 (1.16) 0.757 0.85 (2.29) 0.710 −1.99 (1.91) 0.301
Adjusted model includes following covariates: age, gender, disease duration and baseline SF-36 domain/summary score; cDMARD used as
treatment reference group in TACIT analysis.
BP, bodily pain; cDMARD, combination disease-modifying antirheumatic drug; GH, general health; MCS, mental component summary; MH,
mental health; PCS, physical component summary; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning;
SF-36, Short-Form 36; VT, vitality.
Figure 2 Mean Short-Form 36 (SF-36) domain scores stratified by DAS28-defined disease activity category, and
DAS28-component defined remission in CARDERA. (A) Mean SF-36 domain scores in patients in remission (DAS28<2.6), low
disease activity (LDA; ≥2.6–<3.2), moderate disease activity (MDA; 3.2–5.1) and high disease activity (HDA; >5.1). (B) Mean
scores in patients meeting/not meeting tender joint count (TJC)-defined remission (TJC≤1). (C) Mean scores in patients meeting/
not meeting swollen joint count (SJC)-defined remission (SJC≤1). (D) Mean scores in patients meeting/not meeting patient
global assessment (PtGA) of disease activity-defined remission (100 mm PtGA≤10). (E) Mean scores in patients meeting/not
meeting erythrocyte sedimentation rate (ESR)-defined remission (ESR≤20 mm/hour). These DAS28-component cut-offs
represent the preliminary American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
Boolean-based definition of rheumatoid arthritis (RA) remission for clinical trials. A/G norms=mean SF-36 domain scores in
age-matched and gender-matched individuals from the normative US population. Space between grid lines is 10 units, which
represents twice minimal clinically important differences (MCIDs). BP, bodily pain; GH, general health; MH, mental health; PF,
physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
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Our second aim was to evaluate the impact of
remission and other DAS28-deﬁned disease activity
categories on SF-36 domains at trial end points.
Patients in remission had better HRQoL proﬁles than
patients in higher disease activity states. However,
scores in PF, RP and GH in both trials remained
below normative values, with large deﬁcits observed
in established RA patients enrolled to TACIT. The
IMPROVED trial suggested that in patients with early
inﬂammatory arthritis, attaining prompt remission
normalises HRQoL.23 Overall, these ﬁndings suggest
that in patients with established RA and in some
patients with early RA, attaining remission does not
normalise HRQoL, but attaining early remission in
patients with early inﬂammatory arthritis may be sufﬁ-
cient to achieve this goal.
Our third aim was to assess which DAS28 components
had the strongest associations with HRQoL at trial end
points. In CARDERA and TACIT, PtGA had the strongest
association with PCS and MCS scores; associations with
SJC and ESR levels were weaker. Although different
types of patient-reported outcomes such as PtGA and
SF-36 component summary scores may be expected to
be inter-related, our ﬁnding that PtGA was most strongly
associated with physical and mental HRQoL compared
with other DAS28 components is of clinical importance.
It suggests that in order to optimise HRQoL in RA, it
might be helpful to place an increased focus on improv-
ing PtGA scores. In routine practice, the PtGA is not a
key driver of rheumatologists’ treatment decisions, with
Dutch24 and Canadian25 studies of RA patients demon-
strating that SJC and physician global assessment of
Figure 3 Mean Short-Form 36 (SF-36) domain scores stratified by DAS28-defined disease activity category, and
DAS28-component defined remission in TACIT. (A) Mean SF-36 domain scores in patients in remission (DAS28<2.6), low
disease activity (LDA; ≥2.6–<3.2), moderate disease activity (MDA; 3.2–5.1) and high disease activity (HDA; >5.1). (B) Mean
scores in patients meeting/not meeting tender joint count (TJC)-defined remission (TJC≤1). (C) Mean scores in patients meeting/
not meeting swollen joint count (SJC)-defined remission (SJC≤1). (D) Mean scores in patients meeting/not meeting patient
global assessment (PtGA) of disease activity-defined remission (100 mm PtGA≤10). (E) Mean scores in patients meeting/not
meeting erythrocyte sedimentation rate (ESR)-defined remission (ESR≤20 mm/hour). These DAS28-component cut-offs
represent the preliminary American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
Boolean-based definition of rheumatoid arthritis (RA) remission for clinical trials. A/G norms=mean SF-36 domain scores in an
age-matched and gender-matched normative US population. Space between grid lines is 10 units, which represents twice
minimal clinically important differences (MCIDs). BP, bodily pain; GH, general health; MH, mental health; PF, physical
functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
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disease activity to be central drivers of treatment escal-
ation. As PtGA does not purely reﬂect how active a
patient considers their disease to be—a previous study
by Studenic et al26 showed that 76% and 1.3% of the
variability in PtGA was explained by pain and physical
function, respectively—treatment intensity decisions
should not be based on PtGA alone. However, there is
likely to be a role for more holistic approaches to man-
aging RA patients that move beyond purely targeting
remission, and consider treating other disease impacts
such as pain, fatigue and mood, which are likely to
improve PtGA scores.
The failure of TNFi to improve individual SF-36
domains beyond cDMARDs in TACIT was of interest.
Although limited by a modest sample size, TACIT pro-
vided only little evidence that 6-months TNFi with
DMARDs was superior to cDMARDs at improving
HRQoL. Previous trials of TNFi with methotrexate
versus methotrexate monotherapy in DMARD-IR
patients show signiﬁcant improvements in PCS and
MCS scores with biologics, although the effects are
greater on physical than mental health.6 To our knowl-
edge, only one other study has compared the effect of
TNFi and cDMARDs on HRQoL. A secondary analysis
of the BeST study showed 12-month EuroQol scores
were similar with sequential DMARD monotherapy,
step-up combination DMARDs, initial combination
DMARDs with high-dose tapering prednisolone, and
methotrexate with inﬂiximab, although prompter
improvements were seen in the latter two groups.27
TACIT and BeST suggest TNFis have only limited bene-
ﬁts on HRQoL compared with cDMARDs. There is
insufﬁcient evidence, however, to know if this is correct
in all clinical situations; further large trials are needed
to conﬁrm the relative beneﬁts of different intensive
treatment regimens.
In CARDERA and TACIT SF-36, health proﬁles were
superior in patients attaining remission, compared
with those attaining LDA. This replicates previous
work by Radner et al,28 who reported that in 356 RA
patients with longstanding RA from Austria, remission
gave superior SF-36 proﬁles to LDA. Interestingly, as
in our analysis, Radner et al also found most SF-36
domains in RA patients in remission were below
general population levels. Their ﬁndings therefore
support our view that additional management strat-
egies are needed to normalise HRQoL in addition to
attaining remission.
Our study has several strengths. As a secondary ana-
lysis of two clinical trials, assessments were standardised.
Its main ﬁndings were similar in early and established
RA patients receiving different intensive treatments.
Patients were recruited from many English centres,
which followed consistent healthcare approaches. It also
has several limitations. As a post-hoc analysis, it did not
test a prespeciﬁed hypothesis. It was restricted to asses-
sing treatment impacts in active RA, limiting its general-
isability to all RA populations. It focused on 6-month
and 12-month HRQoL changes; longer time frames
could show greater beneﬁts. It used a generic HRQoL
assessment (SF-36); disease-speciﬁc measures like
RAQoL29 may better capture treatment effects. TACIT
was a non-inferiority trial comparing cDMARDs with
TNFi strategies; our analysis was underpowered to detect
small improvements in SF-36.9 Finally, short-term high-
dose steroids are not widely used in current practice.
Our key ﬁnding that physical HRQoL remained
impaired even when intensive treatment achieved
Table 3 Associations between DAS28 components and SF-36 PCS and MCS at final trial time points
DAS28
component
CARDERA TACIT
Model 1: DAS28
components tested
individually
Model 2: DAS28
components tested in
same model
Model 1: DAS28
components tested
individually
Model 2: DAS28
components tested in
same model
Standardised β
(SE)
p
Value
Standardised β
(SE)
p
Value
Standardised β
(SE)
p
Value
Standardised β
(SE)
p
Value
PCS
SJC −0.45 (0.04) <0.001 −0.19 (0.05) <0.001 −0.24 (0.07) <0.001 −0.06 (0.08) 0.412
TJC −0.33 (0.04) <0.001 0.00 (0.05) 0.977 −0.33 (0.07) <0.001 −0.08 (0.09) 0.370
ESR −0.13 (0.05) 0.005 −0.08 (0.04) 0.036 −0.02 (0.07) 0.804 0.03 (0.07) 0.676
PtGA −0.57 (0.04) <0.001 −0.45 (0.05) <0.001 −0.43 (0.06) <0.001 −0.36 (0.08) <0.001
MCS
SJC −0.29 (0.04) <0.001 −0.12 (0.06) 0.029 −0.16 (0.07) 0.024 0.05 (0.08) 0.527
TJC −0.13 (0.05) 0.004 0.15 (0.05) 0.003 −0.34 (0.07) <0.001 −0.16 (0.09) 0.080
ESR −0.14 (0.05) 0.004 −0.12 (0.04) 0.008 −0.04 (0.07) 0.578 0.00 (0.07) 0.974
PtGA −0.44 (0.04) <0.001 −0.43 (0.05) <0.001 −0.41 (0.06) <0.001 −0.33 (0.08) <0.001
All linear regression models include age, gender, disease duration and treatment as covariates; CARDERA model includes the 24-month
PCS and MCS as the response variables; TACIT model includes the 12-month PCS and MCS as the response variables; the VIFs were <2
for all explanatory variables in model 2.
DAS28, disease activity score; ESR, erythrocyte sedimentation rate; MCS, mental component summary; PCS, physical component summary;
PtGA, patient global assessment of disease activity; SF-36, Short-Form 36; SJC, swollen joint count; TJC, tender joint count.
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remission could reﬂect several underlying drivers. Loss
of lean muscle mass, which is linked with RA disability,30
may occur rapidly in active RA and will not be reversed
with drug treatment. Joint damage, though less common
in contemporary RA cohorts, has detrimental effects on
physical function31 and cannot be reversed by drug
treatment. Persistent pain may also impair physical
health. Finally, clinical remission may be insensitive at
detecting low-level synovitis and inﬂammation, which
could affect physical HRQoL.
Patient surveys suggest current RA management does
not fully address their needs and expectations.32 33 The
‘RAISE patient needs’ survey found few patient–phys-
ician consultations discussed HRQoL.32 The ‘Good Days
Fast’ and ‘Getting to Your Destination Faster’ surveys
found most patients rated ‘having a good day’ as their
preferred target for RA management; being free of
fatigue and pain often characterised ‘good days’.33 In
these surveys, pain was a prevalent problem for patients
with RA. Our ﬁndings suggest that attaining remission,
though crucial to improving RA outcomes, is insufﬁcient
by itself to entirely normalise HRQoL in active RA, par-
ticularly in established disease. New ways are needed to
identify and treat speciﬁcally impaired areas of HRQoL
—including pain and fatigue—as an adjunct to treat-
ments that reduce synovitis assessed by DAS28. Potential
options include using psychological approaches, increas-
ing exercise and improving pain management.
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